Related Experiment Video

Updated: Jan 14, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

604

Next-generation therapeutics for diabetic kidney disease

Tae Won Yi1, Vikas S Sridhar2,3, Jennifer Scott4

  • 1Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Nature Reviews. Nephrology
|January 12, 2026
PubMed

Insights

Diabetic kidney disease (DKD) management involves guideline-directed medical therapies (GDMT), but residual risk remains. Novel therapies are emerging to further improve cardiorenal outcomes in DKD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Diabetic kidney disease (DKD) is a major complication of diabetes mellitus, leading to kidney failure and increased mortality.
  • DKD pathogenesis involves complex hemodynamic, metabolic, and inflammatory pathways driving renal damage.
  • Current treatments offer cardiorenal protection but leave significant residual risk.

Purpose of the Study:

  • To review current management strategies for DKD.
  • To explore emerging next-generation therapies for DKD.
  • To highlight the ongoing need for improved cardiorenal outcomes in DKD.

Main Methods:

  • Literature review of current and developing DKD therapies.
  • Analysis of the pathophysiology of DKD.
  • Synthesis of evidence on guideline-directed medical therapy (GDMT) and novel agents.

Main Results:

  • Current GDMT includes RAS inhibitors, SGLT2 inhibitors, MRAs, and GLP-1 RAs, often used in combination.
  • Despite GDMT, substantial residual cardiorenal risk persists in DKD patients.
  • Numerous next-generation therapies are in development, including incretin-based drugs, ET receptor antagonists, and anti-inflammatory agents.

Conclusions:

  • Optimal GDMT is crucial for managing DKD and reducing cardiorenal risk.
  • Emerging therapies hold promise to complement GDMT and further enhance outcomes.
  • Continued research into novel treatments is essential for improving the prognosis of DKD.

More Related Videos

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.9K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

911

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
333
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
556
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915